Drug Profile
Sabirnetug - Acumen Pharmaceuticals
Alternative Names: ACU-193; Alzheimer's disease immunotherapy - Acumen Pharmaceuticals; anti-ADDL antibodies; HuC-091Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Northwestern University
- Developer Acumen Pharmaceuticals
- Class Antidementias; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Alzheimer's disease
Most Recent Events
- 26 Mar 2024 Acumen Pharmaceuticals plans a phase II ALTITUDE-AD trial for Alzheimer's disease in USA (Intravenous, Infusion) in 1H 2024
- 26 Mar 2024 Acumen Pharmaceuticals plans a phase I trial for Alzheimer's disease (SC) in mid-2024
- 08 Mar 2024 Pharmacodynamics data from a phase I trial in Alzheimer's disease released by Acumen Pharmaceuticals